CDTX News and Press, Cidara Therapeutics Inc. From 03/23/23

2023-03-23 10:06:23 ET Gainers: ZyVersa Therapeutics ( ZVSA ) +33% . Aziyo Biologics ( AZYO ) +29% . Generation Bio ( GBIO ) +20% . HTG Molecular Diagnostics ( HTGM ) +16% . scPharmaceuticals ( SCPH ) +15% . Losers:...

2023-03-23 08:27:39 ET Society Pass ( SOPA ) -22% on Q4 earnings release . JanOne ( JAN ) -15% on $422K stock offering . Coinbase Global ( COIN ) -12% as SEC warns of potential charges ; downgraded to Perform at Oppenheimer after Wells n...

2023-03-23 07:53:26 ET Cidara Therapeutics press release ( NASDAQ: CDTX ): Q4 GAAP EPS of -$0.19 misses by $0.04 . Revenue of $10.22M (+41.9% Y/Y) misses by $0.35M . Cash and cash equivalents totaled $32.7 million as of December 31, 2022, co...

SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today reported financial results for the three months and full ye...

2023-03-23 04:49:08 ET The U.S. Food and Drug Administration (FDA) approved Cidara Therapeutics ( NASDAQ: CDTX ) and Melinta Therapeutics' Rezzayo (rezafungin for injection) to treat candidemia and invasive candidiasis in adults with limited or no alternative treatment...

– REZZAYO is a novel, once-weekly, next-generation echinocandin indicated for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options – – REZZAYO is the first new FDA-approved echinocandin in over a decade ȁ...

– REZZAYO is a novel, once-weekly, next-generation echinocandin indicated for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options – – REZZAYO is the first new FDA-approved echinocandin in over a decade ...

2023-03-22 08:21:40 ET 89bio ( ETNB ) +50% on topline data for NASH candidate. GameStop ( GME ) +48% on Q4 earnings. Telesis Bio ( TBIO ) +17% on Q4 earnings. Pyxis Oncology ( PYXS ) +11% on Q4 earnings. Ollie's Bargain O...

2023-03-22 08:17:48 ET After reaching a 52-week high in the previous session, Cidara Therapeutics ( NASDAQ: CDTX ) continued to trade higher in the pre-market Wednesday as the biotech awaits the FDA decision on its antifungal therapy rezafungin. In September, the FDA accep...

2023-03-18 10:30:11 ET Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports a...